Equities

Liaoning Chengda Biotechnology Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Liaoning Chengda Biotechnology Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)25.90
  • Today's Change0.00 / 0.00%
  • Shares traded1.06m
  • 1 Year change-8.42%
  • Beta1.2261
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Liaoning Chengda Biotechnology Co Ltd is a China-based company mainly engaged in the research and development, production and sales of human vaccines. The Company's products include rabies vaccine for human use and inactivated Japanese encephalitis vaccine. The Company has completed the construction of bacterial vaccine technology platform, viral vaccine technology platform, multi-component multivalent vaccine technology platform and recombinant protein vaccine technology platform. The Company mainly conducts its businesses in the domestic and foreign markets.

  • Revenue in CNY (TTM)1.47bn
  • Net income in CNY177.94m
  • Incorporated2002
  • Employees1.81k
  • Location
    Liaoning Chengda Biotechnology Co LtdNo. 1Xinfang Street, Hunnan New DistrictSHENYANG 110179ChinaCHN
  • Phone+86 2 483782632
  • Fax+86 2 423789772
  • Websitehttps://www.cdbio.cn
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Chongqing Taiji Industry Group Co Ltd10.04bn-352.52m9.90bn11.97k--2.80--0.9859-0.8238-0.823818.986.420.70322.853.55838,688.20-2.360.9924-6.943.0426.3043.37-3.351.080.49060.57560.591422.39-20.721.24-96.76---3.36--
Chengdu Olymvax Biopharmaceuticals Inc709.13m64.21m9.90bn470.00153.7410.32--13.960.15870.15871.752.360.38830.6541.191,508,792.003.453.255.004.8192.6693.628.888.111.428.300.29067.3918.6926.8818.24--48.00--
Youcare Pharmaceutical Group Co Ltd2.55bn-233.99m10.24bn3.28k--2.99--4.02-0.5306-0.53065.757.620.45372.184.03777,123.10-4.305.90-5.978.9247.5563.64-9.487.491.49-41.240.163366.99-9.90-2.48-33.05-15.4019.36--
Chongqing Genrix Biophrmctcl Co Ltd225.16m-583.52m10.63bn743.00--5.94--47.19-1.59-1.590.61414.880.07120.308810.33303,044.90-18.45---19.95--90.99---259.16--7.37--0.3694--2,384.11--0.5049------
Liaoning Chengda Biotechnology Co Ltd1.47bn177.94m10.79bn1.81k59.811.15--7.340.4330.4333.5622.540.14820.67861.24813,192.101.798.071.868.3679.0384.9812.1135.7519.28--0.001344.77-4.22-0.0082-26.42-13.26-4.72--
Jiangsu Sinopep Allsin Bphrmctcl Co Ltd1.90bn498.69m10.94bn2.03k21.713.52--5.761.601.606.139.840.34130.93063.06936,748.908.907.1913.049.6766.6459.3026.0820.280.92816.070.460435.8957.2134.33148.1952.7631.58--
Aurisco Pharmaceutical Co Ltd1.62bn424.54m10.98bn1.78k25.564.32--6.761.061.064.076.260.41881.094.41910,578.1010.9411.3712.6013.2959.7752.9326.1322.343.01635.150.280631.5316.8920.4722.5913.7749.45--
Shanghai Yizhong Pharmaceutical Co Ltd247.05m22.96m11.30bn65.00483.127.74--45.750.11320.11321.227.070.1630.95562.263,800,801.001.515.441.585.6481.3992.999.3036.907.84--0.0032.30-51.83---95.68--10.96--
Zhejiang CONBA Pharmaceutical Co., Ltd.6.58bn687.99m11.46bn8.26k16.961.62--1.740.26650.26652.542.800.66172.574.70796,529.007.138.519.6512.7451.8858.6410.7714.121.38--0.053241.54-3.23-0.75945.21--1.57--
Cansino Biologics Inc971.83m-142.03m11.61bn1.11k--3.06--11.95-0.5455-0.54553.9221.370.12710.58611.38879,482.50-1.86-4.08-2.29-5.3878.8045.31-14.62-27.513.29--0.2242--137.01226.4374.45--31.38--
Data as of Feb 11 2026. Currency figures normalised to Liaoning Chengda Biotechnology Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

2.73%Per cent of shares held by top holders
HolderShares% Held
China Asset Management Co., Ltd.as of 30 Jun 20252.04m0.49%
China Southern Asset Management Co., Ltd.as of 30 Jun 20252.03m0.49%
Bosera Asset Management Co., Ltd.as of 30 Jun 20251.56m0.37%
Penghua Fund Management Co., Ltd.as of 30 Jun 20251.45m0.35%
The Vanguard Group, Inc.as of 07 Jan 20261.13m0.27%
GF Fund Management Co., Ltd.as of 30 Jun 2025907.07k0.22%
Yinhua Fund Management Co., Ltd.as of 30 Jun 2025741.82k0.18%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 2025531.92k0.13%
Guotai Asset Management Co., Ltd.as of 30 Jun 2025514.85k0.12%
E Fund Management Co., Ltd.as of 30 Jun 2025480.63k0.12%
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.